Using objective markers and imaging in the development of novel treatments of chronic pain

Chizh, Boris A.; Hobson, Anthony

doi:10.1586/14737175.7.5.443

Cited by 6 publications

(6 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The field of pain management would benefit enormously from an objective, physiologic marker of pain [18]. Several physiologic variables have been measured for this purpose, such as skin conductance [19] and heart rate [20].…”

Section: What About An Objective Marker Of Pain?mentioning

confidence: 99%

Pain outcomes: A brief review of instruments and techniques

Younger

McCue²,

Mackey³

2009

Current Science Inc

288

218

View full text Add to dashboard Cite

Pain is a difficult outcome to measure due to its multifaceted and subjective nature. The need for selecting proper outcome measures is high because of the increasing demand for scientifically valid demonstrations of treatment efficacy. This article discusses some basic topics in the measurement of pain outcomes and addresses issues such as statistical versus clinical significance, daily home data collection, appropriate length of outcome measurement packets, and the possibility of objective pain measurements. This article also reviews some of the more commonly used tools for measuring pain and pain-related disability. By selecting the proper tools and employing them correctly, we can obtain highly reliable and valid measures of pain outcomes in research and clinical care.

show abstract

Section: What About An Objective Marker Of Pain?mentioning

confidence: 99%

Pain outcomes: A brief review of instruments and techniques

Younger

McCue²,

Mackey³

2009

Current Science Inc

288

218

View full text Add to dashboard Cite

show abstract

“…As well as being important as a translational technology from preclinical experiments to the clinic, imaging is beginning to make a real difference to the ability to carry out clinical trials of disease modifying agents in neurological disorders (cf., 57 ). The most extensive technology developments have occurred in positron emission tomography (PET) imaging and in structural and functional magnetic resonance imaging (fMRI).…”

Section: The Importance Of Imagingmentioning

confidence: 99%

Animal and Translational Models of Neurological Disorders: An Industrial Perspective

Hunter¹

2008

Animal and Translational Models for CNS Drug Discovery

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…2007; Zin et al. 2010), and imaging of the pain matrix (Chizh and Hobson 2007; Tracey and Mantyh 2007), and more recently via pain phenotyping (von Hehn et al. 2012), but none are well accepted as objective biomarkers at present.…”

mentioning

confidence: 99%

“…Biomarkers should be distinguished from surrogate endpoints, for which stringent qualification is required to enable the surrogate to substitute for a clinical endpoint (NIH Biomarkers Working Group 2001). Biomarker development for neuropathic pain has had some potential leads in genetics (Foulkes and Wood 2008), quantification of primary afferent activity (Chizh and Hobson 2007), sampling the cerebrospinal fluid (Uceyler et al 2007;Zin et al 2010), and imaging of the pain matrix (Chizh and Hobson 2007;Tracey and Mantyh 2007), and more recently via pain phenotyping (von Hehn et al 2012), but none are well accepted as objective biomarkers at present. An objective measure of pain intensity may prove a useful adjunct to the visual analogue scale and other subjective measures of pain reporting in a clinical scenario, to overcome the difficulties associated with inter-individual differences in reporting experiences or using rating scales, and when a subjective report cannot be solely relied upon (e.g.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Harnessing pain heterogeneity and RNA transcriptome to identify blood‐based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model

Grace

Hurley

Barratt

et al. 2012

Journal of Neurochemistry

View full text Add to dashboard Cite

A quantitative, peripherally accessible biomarker for neuropathic pain has great potential to improve clinical outcomes. Based on the premise that peripheral and central immunity contribute to neuropathic pain mechanisms, we hypothesized that biomarkers could be identified from the whole blood of adult male rats, by integrating graded chronic constriction injury (CCI), ipsilateral lumbar dorsal quadrant (iLDQ) and whole blood transcriptomes, and pathway analysis with pain behavior. Correlational bioinformatics identified a range of putative biomarker genes for allodynia intensity, many encoding for proteins with a recognized role in immune/nociceptive mechanisms. A selection of these genes was validated in a separate replication study. Pathway analysis of the iLDQ transcriptome identified Fcγ and Fcε signaling pathways, among others. This study is the first to employ the whole blood transcriptome to identify pain biomarker panels. The novel correlational bioinformatics, developed here, selected such putative biomarkers based on a correlation with pain behavior and formation of signaling pathways with iLDQ genes. Future studies may demonstrate the predictive ability of these biomarker genes across other models and additional variables.

show abstract

Using objective markers and imaging in the development of novel treatments of chronic pain

Cited by 6 publications

References 62 publications

Pain outcomes: A brief review of instruments and techniques

Pain outcomes: A brief review of instruments and techniques

Animal and Translational Models of Neurological Disorders: An Industrial Perspective

Harnessing pain heterogeneity and RNA transcriptome to identify blood‐based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model

Contact Info

Product

Resources

About